Allogene Therapeutics, Inc. ALLO
0.63 USD -0.04 (-5.88%)
Regular-session close
0.63 +0.01 +1.12%
After hours · Nov 20, 7:37 PM ET
0.6192 Day range 0.67
0.6277 52-week range 3.06
- YTD
- -54.18%
- 1 year
- -49.38%
News
seekingalpha.com Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Allogene Therapeutics Announces Preliminary Safety, Efficacy And Translational Data From Its Phase 1 RESOLUTION Trial Of ALLO-329 At American College Of Rheumatology Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today…
benzinga.com Allogene Therapeutics Q3 2026 Earnings Call Transcript Allogene Therapeutics (NASDAQ:ALLO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Allogene Therapeutics Q3 EPS $(0.15), Inline Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 21.05 percent increase over losses of $(0.19) per share from the…
